A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial of Adjuvant Avelumab (Anti-PDL-1 Antibody) in Merkel Cell Carcinoma Patients With Clinically Detected Lymph Node Metastases
Phase of Trial: Phase III
Latest Information Update: 03 Jan 2019
At a glance
- Drugs Avelumab (Primary)
- Indications Cancer metastases; Merkel cell carcinoma
- Focus Therapeutic Use
- Acronyms ADAM
- 31 Aug 2018 Biomarkers information updated
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 28 Nov 2017 Status changed from not yet recruiting to recruiting.